c-di-AMP sodium (Synonyms: c-di-AMP, Cyclic di-Adenosine monophosphate, 3',5'-Cyclic diadenylic acid, Cyclic diadenylate) |
| Catalog No.GC62198 |
C-di-AMP is a STING agonist, which binds to the transmembrane protein STING, thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2734909-87-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
C-di-AMP is a STING agonist, which binds to the transmembrane protein STING, thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP serves as a second messenger in bacteria, primarily regulating cell growth, survival, and virulence in Gram-positive bacteria, and also modulates the host immune response. As an effective mucosal adjuvant, c-di-AMP stimulates both humoral and cellular responses[1-5]. C-di-AMP have been utilized as vaccine adjuvants for influenza and hepatitis C.Citation[6].
Combination of c-di-AMP(5 ug/ml;48h) with radiation promotes the secretion of type I IFN and ISG levels in BMDCs[7].
C-di-AMP(25ug;i.p;3 times) can synergistically enhance the antitumor effects of Radiotherapy (RT)-associated dsDNA by promoting IFN-β production and CD8+ cytolytic T cell activation in a cGAS- and STING-dependent manner in mice[7].
References:
[1]. Jenal U, Reinders A, et,al.Cyclic di-GMP: second messenger extraordinaire. Nat Rev Microbiol. 2017 May;15(5):271-284. doi: 10.1038/nrmicro.2016.190. Epub 2017 Feb 6. PMID: 28163311.
[2]. Fahmi T, Port GC, et,al.c-di-AMP: An Essential Molecule in the Signaling Pathways that Regulate the Viability and Virulence of Gram-Positive Bacteria. Genes (Basel). 2017 Aug 7;8(8):197. doi: 10.3390/genes8080197. PMID: 28783096; PMCID: PMC5575661.
[3]. Ning H, Wang L, et,al. Recombinant BCG With Bacterial Signaling Molecule Cyclic di-AMP as Endogenous Adjuvant Induces Elevated Immune Responses After Mycobacterium tuberculosis Infection. Front Immunol. 2019 Jul 3;10:1519. doi: 10.3389/fimmu.2019.01519. PMID: 31333655; PMCID: PMC6618344.
[4]. Ebensen T, Delandre S, et,al. The Combination Vaccine Adjuvant System Alum/c-di-AMP Results in Quantitative and Qualitative Enhanced Immune Responses Post Immunization. Front Cell Infect Microbiol. 2019 Feb 19;9:31. doi: 10.3389/fcimb.2019.00031. PMID: 30838180; PMCID: PMC6390046.
[5]. Sanchez MV, Ebensen T, et,al. Intranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellular immune responses and provides protection against virus challenge. PLoS One. 2014 Aug 20;9(8):e104824. doi: 10.1371/journal.pone.0104824. PMID: 25140692; PMCID: PMC4139298.
[6]. Yin W, Cai X, et,al. A decade of research on the second messenger c-di-AMP. FEMS Microbiol Rev. 2020 Nov 24;44(6):701-724. doi: 10.1093/femsre/fuaa019. PMID: 32472931; PMCID: PMC7850090.
[7]. Li Z, Zhang Y, et,al. Gut microbiota modulate radiotherapy-associated antitumor immune responses against hepatocellular carcinoma Via STING signaling. Gut Microbes. 2022 Jan-Dec;14(1):2119055. doi: 10.1080/19490976.2022.2119055. PMID: 36093568; PMCID: PMC9467592.
| Cell experiment [1]: | |
|
Cell lines |
Bone marrow- derived DC(BMDC) |
|
Preparation Method |
BMDCs were stimulated with irradiated tumor-supernatants, or c-di-AMP (5 ug/ml) or a combination for 48 h on day 7. |
|
Reaction Conditions |
5 ug/ml;48h |
|
Applications |
Combination of c-di-AMP with radiation promotes the secretion of type I IFN and ISG levels. |
| Animal experiment [2]: | |
|
Animal models |
C57BL/6 male mice and cGAS KO (Mb21d1-/-) mice |
|
Preparation Method |
Mice were injected c-di-AMP intraperitoneally with 25ug one day before radiotherapy, and once every other day, a total of three times. |
|
Dosage form |
25ug;i.p;3 times |
|
Applications |
C-di-AMP acts as STING agonist, cooperated with dsDNA to promote DC maturation and type I IFN release. |
|
References: [1]. Li Z, Zhang Y, et,al. Gut microbiota modulate radiotherapy-associated antitumor immune responses against hepatocellular carcinoma Via STING signaling. Gut Microbes. 2022 Jan-Dec;14(1):2119055. doi: 10.1080/19490976.2022.2119055. PMID: 36093568; PMCID: PMC9467592. |
|
| Cas No. | 2734909-87-4 | SDF | |
| Synonyms | c-di-AMP, Cyclic di-Adenosine monophosphate, 3',5'-Cyclic diadenylic acid, Cyclic diadenylate | ||
| Formula | C20H22N10Na2O12P2 | M.Wt | 702.38 |
| Solubility | DMSO : 270 mg/mL (384.41 mM; Need ultrasonic); H2O : ≥ 50 mg/mL (71.19 mM) | Storage | Store at -80°C, protect from light, stored under nitrogen |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4237 mL | 7.1187 mL | 14.2373 mL |
| 5 mM | 0.2847 mL | 1.4237 mL | 2.8475 mL |
| 10 mM | 0.1424 mL | 0.7119 mL | 1.4237 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 37 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *